Autonomix Medical reports promising pain relief in pancreatic cancer

Autonomix Medical, Inc. ( (AMIX) ) has issued an update.

On January 9, 2026, Autonomix Medical reported new subgroup clinical data from its ongoing Proof-of-Concept 1 study, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, showing that its transvascular RF denervation platform produced rapid, durable and clinically meaningful pain relief in pancreatic cancer patients across disease stages 2 through 4. The post hoc analysis found that responding patients experienced marked reductions in pain within 24 hours, with nearly all improving from severe to mild or moderate pain at seven days, about two-thirds maintaining mild or near-elimination pain levels at four to six weeks, and none reporting severe pain at three months, including late-stage patients with limited treatment options, underscoring the platform’s potential to significantly improve palliative care in advanced pancreatic cancer and reinforcing Autonomix’s positioning in nerve-targeted oncology pain management.

The most recent analyst rating on (AMIX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autonomix Medical, Inc. stock, see the AMIX Stock Forecast page.

Spark’s Take on AMIX Stock

According to Spark, TipRanks’ AI Analyst, AMIX is a Underperform.

Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.

To see Spark’s full report on AMIX stock, click here.

More about Autonomix Medical, Inc.

Autonomix Medical, Inc. is a medical device company focused on developing innovative, precision nerve-targeted technologies to diagnose and treat diseases involving the nervous system. Its first-in-class, catheter-based microchip sensing platform is being initially developed for the treatment of severe pain in pancreatic cancer, with broader potential applications across cardiology, hypertension and chronic pain management. The company’s technology remains investigational and is not yet cleared for marketing in the United States.

Average Trading Volume: 7,668,004

Technical Sentiment Signal: Sell

Current Market Cap: $3.42M

See more insights into AMIX stock on TipRanks’ Stock Analysis page.